Recruiting nowNot phasedRandomised
What this trial is trying to do
The researchers are testing whether ropivacaine, a local anaesthetic that numbs pain-sensing nerve branches supplying the abdominal wall, adds useful pain relief when delivered through rectus sheath catheters after a midline laparotomy. It is compared with saline catheters as part of otherwise multimodal pain treatment.
The idea is that extra local anaesthesia could reduce pain, opioid use and the burden of recovery after surgery, potentially improving patient satisfaction and recovery scores. The trial measures maximum pain, morphine-equivalent opioid consumption and recovery during the first 72 hours after surgery.
Worth knowing: This is a small, 40-person perioperative study, so it is testing short-term pain and recovery outcomes rather than longer-term cancer or survival outcomes.
Written from the trial's own registry entry to explain what the researchers are testing and why. Nothing here is a result — this trial has not reported one — and it is not a view on whether the treatment works or on whether it would suit you.
| Registry number | NCT07099924 |
|---|---|
| Recruitment | Recruiting now |
| Phase | Not phased |
| Design | randomised, blinded |
| Taking part | 40 people (planned) |
| Who can join | aged 18 Years and over |
| Run by | Asklepios Kliniken Hamburg GmbH |
| Started | |
| Main results expected | |
| Record last updated |
What is being tested
- Drug Ropivacaine 0.2%
- Drug Saline 0.9%
What it is measuring
patient satisfaction
This is the trial's main question — the one it is designed and sized to answer. Anything else it reports is a secondary finding, and secondary findings are far more likely to be chance.
Not phased. Not a drug-phase trial. Often a device, a procedure, or a change in how care is delivered.
How the researchers describe it
Rectus sheath catheters (RSC) are used for postoperative analgesia following midline laparotomies. Local anesthetics are applied to the posterior rectus sheath via the RSC. The target structures are the anterior cutaneous branches of the spinal nerves Th7-Th12. RSC can be used in particular if thoracic epidurals are contraindicated (compromised coagulation), technically unfeasible or refused by the patient.
The study investigates placebo-controlled weather RSC have a significant additional analgesic effect in a multimodal analgesic concept. Primary outcome parameters are the maximum pain score, the Quality-of-Recovery-15-Score (QoR-15GE) and the opioid consumption (morphine equivalents) in the first 72h postoperatively.
Written by the trial’s sponsor, quoted from its ClinicalTrials.gov record.
What this trial is looking for
- Any genotype
Read automatically from the criteria below, to make the list searchable. It is a summary of what the text mentions, not a decision about whether you qualify — and where the two disagree, the criteria are right and this is wrong.
Who the trial is looking for
Inclusion Criteria
- Median laparotomy
- Age over 18 years
- Informed consent has been obtained
Exclusion Criteria
- Local signs of inflammation
- known allergy to local anesthetics used
- chronic pain syndrome
- drug addiction
- post-operative ventilation that cannot be completed on the day of surgery
- lack of consent or cooperation
- pregnancy
- participation in another medical study
- sepsis
This is an extract. Whether you qualify is decided by the trial team against the full criteria, not by reading this page. Read the full eligibility criteria
Where it is running
Running at 1 site. Listed in: Germany.
Individual hospitals, and whether each is currently open, are listed on the registry record. Sites open and close throughout a trial.
Worth asking your oncology team
Being listed here is not a recommendation, and no one page can tell you whether a trial is right for you. These are the questions it raises.
- Is this trial open at a hospital I could realistically travel to?
- Given my stage, my previous treatment and my tumour's molecular profile, would I be eligible?
- What would I be giving up by joining — is the comparison arm the treatment I would otherwise be having?
- What is already known about the safety of what is being tested?
The source
Registry record NCT07099924, registered by Asklepios Kliniken Hamburg GmbH on ClinicalTrials.gov, a public database run by the US National Library of Medicine. The details on this page come from that record and are only ever as current as the sponsor has kept it.
This is a listing of a registered clinical trial, reproduced for information. It is not a recommendation, this site has no connection to the trial or its sponsor, and being listed here says nothing about whether the treatment works. Talk to your own oncology team before pursuing any trial.
This article summarises published research for general information. It is not medical advice, and it is not a substitute for a conversation with your own oncology team, who know your case. Do not start, stop, or change any treatment or supplement on the basis of what you read here.